HYPERCALCIURIC NEPHROLITHIASIS TRIAL BETWEEN UROPHOS-K AND UROCIT-K

说明：(直接取自药材)吸收性高钙尿症是一种结石形成的情况，高钙尿症被认为是由于肠道钙吸收的原发增强所致。吸收性高钙尿症的起源可能是异质性的，大致可分为维生素D非依赖型和维生素D依赖型。因此，除了复发性肾结石外，吸收性高钙尿尚不清楚，但我们已暗示骨化三醇过量的分解代谢作用可能起作用。因此，由于目前的长期治疗并不令人满意，理想的治疗方法应该是持续纠正肠道和肾脏钙的过度吸收和排泄，避免骨丢失。这种需要导致了我们的假设，即一种特殊的正磷酸盐配方(缓释中性磷酸钾或UroPhos-K)将纠正高钙尿，防止复发结石形成，并提供安全的使用安全性，用于治疗因吸收性高钙尿引起的高钙尿性肾结石。在一项对照随机试验中，将比较UroPhos-K和Urocit-K(柠檬酸钾)在高钙尿症伴吸收性高钙尿患者中的疗效。需要检验的假设是，与Urocit-K不同，UroPhos-K会降低尿钙，并且在抑制新结石形成方面比Urocit-K更有效。UroPhos-K抑制新结石形成的安全性和积极的物理化学和生理效应。正在进行的长期非随机试验披露的UroPhos-K的安全性和积极的物理化学和生理效应为启动这项随机试验提供了动力。

Description: (Taken Directly from the application) Absorptive hypercalciuria is a stone-forming condition in which hypercalciuria is believed to result from the primary enhancement of intestinal calcium absorption. Absorptive hypercalciuria is probably heterogeneous in origin, and may be broadly categorized into vitamin D-independent and vitamin D-dependent forms. Thus, besides recurrent nephrolithiasis, absorptive hypercalciuria is not known, but we have implicated a potential role of the catabolic skeletal effect of calcitriol excess. Therefore, since current long-term treatment is far from satisfactory, an ideal treatment should be one which produces a sustained correction of excessive intestinal absorption and renal excretion of calcium, and averts bone loss. This need has led to our hypothesis that a special formulation of orthophosphate (slow-release neutral potassium phosphate or UroPhos-K) would correct hypercalciuria, prevent recurrent stone formation and provide safety of usage in hypercalciuric nephrolithiasis due to absorptive hypercalciuria. In a controlled randomized trial, the effect of UroPhos-K will be compared with that of Urocit-K (potassium citrate) in hypercalciuric patients with absorptive hypercalciuria. The hypothesis to be tested is that UroPhos-K would lower urinary calcium unlike Urocit-K, and would be more effective than Urocit-K in inhibiting new stone formation. The safety and positive physicochemical and physiological effects of UroPhos-K in inhibiting new stone formation. The safety and positive physicochemical and physiological effects of UroPhos-K disclosed from ongoing long-term non-randomized trial provided the impetus to initiate this randomized trial.